Valneva SE Sponsored ADR (NASDAQ:VALN – Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $5.59, but opened at $6.17. Valneva shares last traded at $6.4150, with a volume of 34,411 shares trading hands.
Analyst Ratings Changes
A number of research firms recently weighed in on VALN. The Goldman Sachs Group lowered Valneva from a “neutral” rating to a “sell” rating and set a $4.90 target price on the stock. in a report on Wednesday, April 22nd. Wall Street Zen downgraded Valneva to a “strong sell” rating in a research report on Saturday, April 25th. Finally, Guggenheim set a $11.00 target price on Valneva in a research report on Thursday, April 16th. Three investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $11.98.
Check Out Our Latest Stock Analysis on VALN
Valneva Stock Up 12.9%
Valneva (NASDAQ:VALN – Get Free Report) last issued its earnings results on Sunday, February 15th. The company reported ($0.68) earnings per share for the quarter. Valneva had a negative return on equity of 76.81% and a negative net margin of 67.64%.The business had revenue of $55.92 million during the quarter. On average, research analysts predict that Valneva SE Sponsored ADR will post -0.81 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd purchased a new position in shares of Valneva during the 4th quarter valued at $94,000. China Universal Asset Management Co. Ltd. bought a new position in Valneva in the 4th quarter worth about $44,000. JPMorgan Chase & Co. bought a new position in Valneva in the 3rd quarter worth about $124,000. VSM Wealth Advisory LLC increased its stake in Valneva by 125.0% in the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Marex Group plc bought a new position in Valneva in the 2nd quarter worth about $64,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.
About Valneva
Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.
Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.
Further Reading
- Five stocks we like better than Valneva
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
